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Abstract
Background: Influenza viral shedding studies provide fundamental information for preventive strategies and modelling
exercises. We conducted a prospective household study to investigate viral shedding in seasonal and pandemic influenza
between 2007 and 2011 in Berlin and Munich, Germany.
Methods: Study physicians recruited index patients and their household members. Serial nasal specimens were obtained
from all household members over at least eight days and tested quantitatively by qRT-PCR for the influenza virus (sub)type
of the index patient. A subset of samples was also tested by viral culture. Symptoms were recorded daily.
Results: We recruited 122 index patients and 320 household contacts, of which 67 became secondary household cases.
Among all 189 influenza cases, 12 were infected with seasonal/prepandemic influenza A(H1N1), 19 with A(H3N2), 60 with
influenza B, and 98 with A(H1N1)pdm09. Nine (14%) of 65 non-vaccinated secondary cases were asymptomatic/subclinical
(0 (0%) of 21 children, 9 (21%) of 44 adults; p = 0.03). Viral load among patients with influenza-like illness (ILI) peaked on
illness days 1, 2 or 3 for all (sub)types and declined steadily until days 7–9. Clinical symptom scores roughly paralleled viral
shedding dynamics. On the first day prior to symptom onset 30% (12/40) of specimens were positive. Viral load in 6
asymptomatic/subclinical patients was similar to that in ILI-patients. Duration of infectiousness as measured by viral culture
lasted approximately until illness days 4–6. Viral load did not seem to be influenced by antiviral therapy, age or vaccination
status.
Conclusion: Asymptomatic/subclinical infections occur infrequently, but may be associated with substantial amounts of
viral shedding. Presymptomatic shedding may arise in one third of cases, and shedding characteristics appear to be
independent of (seasonal or pandemic) (sub)type, age, antiviral therapy or vaccination; however the power to find
moderate differences was limited.
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Introduction
Influenza viral shedding studies are important as they help to
understand the epidemiology of the virus and form the basis for
rational preventive strategies. Among the parameters that can be
obtained from viral shedding studies are the degree of viral
shedding before/after symptom onset, duration of viral shedding,
course of clinical symptoms, serial interval, age dependency of the
shedding profile and proportion of asymptomatic/subclinical
infections. Furthermore, results such as incubation period or
latency period can be used for the parameterization of modelling
studies on population level[1–3]. Finally, mathematical manipu-
lation of data can aid to estimate the basic reproduction number,
the recovery rate or the proportion of transmission events prior to
symptoms [4].
Before the influenza A(H1N1)pdm09 pandemic volunteer
challenge studies with seasonal virus (sub)types had been
conducted and were summarized in a meta-analysis by Carrat
et al. in 2008 [5]. On the other hand studies investigating
shedding properties of the A(H1N1)pdm09 virus have been based
on naturally occurring infections, therefore limiting comparability.
To date only two studies have compared shedding and symptom
characteristics of the pandemic A(H1N1)pdm09 virus with
seasonal, pre-pandemic influenza virus [6,7]. However, both
studies did not include shedding dynamics of influenza B. In
addition, although both have addressed asymptomatic and
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presymptomatic shedding the number of individuals where these
aspects could be investigated was limited.
We conducted a prospective household based study of seasonal
(A(H3N2), A(H1N1), B), and pandemic (A(H1N1)pdm09) in-
fluenza during four consecutive influenza seasons from 2007/2008
to 2010/2011 in Berlin and Munich, Germany. Objectives were to
describe shedding dynamics and course of illness by (sub)type and
age, to compare shedding dynamics in asymptomatic (subclinical)
vs. symptomatic patients, in vaccinated vs. non-vaccinated
patients, as well as in those treated with oseltamivir vs. those not
treated, and to describe the relationship of molecular viral load
with results using tissue-culture methods.
Methods
Recruitment and Follow-up of Participants
From general practitioners and pediatricians in Berlin and
Munich (Germany) we recruited influenza households during four
consecutive influenza seasons: January 2008-April 2008 (season 1 -
dominated by seasonal/prepandemic influenza A(H1N1) and
influenza B), January 2009-April 2009 (season 2 - dominated by
influenza A(H3N2) and influenza B), November 2009-January
2010 (season 3 - dominated by influenza A(H1N1)pdm09), and
January-April 2011 (season 4 - dominated by influenza
A(H1N1)pdm09 and influenza B). Munich was a study site only
in seasons 1 and 2. During seasons 3 and 4, the study was
embedded in a cluster randomised trial on the effectiveness of
facemasks and hand hygiene to reduce influenza transmission in
households [8].
Household index patients eligible for inclusion had to have
influenza-like illness (defined as fever and [cough or sore throat])
and to present at the recruiting physician within two days of
symptom onset, had to have a positive rapid antigen test for
influenza (later to be confirmed by quantitative reverse transcrip-
tion polymerase chain reaction [qRT-PCR]), and had to be more
than two years of age. Exclusion criteria were pregnancy, severely
reduced health status, HIV infection, and belonging to a single
person household.
We obtained written informed consent from all study partici-
pants. If these were less than 18 years of age we asked their parents
or legal guardians to provide proxy written consent, with
additional written consent from those participants aged 14 to 17
years of age.
The observation period for each household lasted 8 days,
starting on the day of symptom onset or up to two days after
symptom onset of the index patient counting the day of symptom
onset as day 1 for the household. We collected specimens and data
from all household members. Household visits were scheduled
daily during the observation period of seasons 1 and 2 and on days
2, 3, 4, 6, and 8 (five times) or on days 3, 4, 6, and 8 (four times)
depending on the day of recruitment in seasons 3 and 4. If one of
the household contacts developed symptoms (fever/chills, cough
or sore throat) and was laboratory confirmed as a secondary case
two further visits were scheduled for days 10 and 12.
Specimen Collection
During all household visits we obtained nasal wash specimens
(or – if these were not possible – nasal swabs) from all participating
household members. For the collection of nasal wash, we used
5 mL of isotonic saline, which were instilled into one nostril with
participant’s heads tilted backwards. Participants were asked to
remain in this position for 10–15 s while making hard ‘K’ sounds
without swallowing. Subsequently, the participants were told to tilt
their heads forward and the fluid was collected in a sterile cup [9].
Nasal swabs were collected by using virus transport swabs
(MastaswabTM; MAST Diagnostica, Reinfeld, Germany). A
subgroup of participants (aged 14 years or older) in seasons 1
and 2 agreed to provide blood samples (a maximum of five EDTA
samples per participant collected before symptom onset, on the
day of symptom onset, and on the first three after symptom onset).
Additionally in seasons 1 and 2, index patients were asked to
Figure 1. Study flow diagram.
doi:10.1371/journal.pone.0051653.g001
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provide one stool sample on one of the first three illness days.
Samples were stored refrigerated (at a temperature of approxi-
mately 5uC) before analysis with the exception of samples tested by
viral culture which were stored frozen (at approximately 280uC)
before analysis (see below) [10].
After the first household visit, all participants self-recorded
symptoms (fever, shivering, measured temperature, cough, sore
throat) in a daily monitoring questionnaire. We defined children
as persons aged less than 14 years, adults were at least 14 years
old. ‘‘Timely antiviral therapy’’ (if prescribed by their physician)
started within two days of symptom onset. We defined
a symptomatic secondary influenza virus infection as a laboratory
confirmed influenza infection in a household member who
developed fever (.38.0uC), cough, or sore throat in the
observation period. We termed all other secondary cases as
asymptomatic/subclinical.
For the assessment of viral shedding profiles among symptom-
atic patients we used as the day of symptom onset the day when
the patient had fever, cough or sore throat for the first time. If the
last available specimen of a participant was negative we assumed
that viral shedding had ceased. To assess viral shedding in
asymptomatic/subclinical individuals we restricted analysis to
those who had two negative samples before the first positive
sample and who had at least one further sample taken after the
first positive sample. To exclude the possibility that this positive
sample was taken on the first presymptomatic day (i.e. followed by
onset of symptoms on the next day) we assured that no fever,
cough or sore throat was present on the day (or any other day)
after the day of the first positive sample. To describe the course of
illness we calculated a daily symptom severity score on a four level
scale from 0 (not present) to 3 (severe) for each of the following
symptoms: fever/chills, cough, and sore throat. Thus the daily












Index Cases – n 122 6 8 38 70
Age (years) – median (IQR) 8.1 (6.0) 6.5 (5–12) 6.5 (2–11) 7 (5–10) 8 (5–10)
Age,14 years – n/n (%) 113/122 (93) 5/6 (83) 7/8 (88) 35/38 (92) 66/70 (94) 0.7
Sex, male – n/n (%) 72/122 (59) 4/6 (67) 4/8 (50) 24/38 (63) 40/70 (57) 0.9
Vaccinated* – n/n (%) 5/122 (4) 1/6 (17) 0/8 3/38 (8) 1/70 (1) 0.1
Antiviral Therapy** – n/n (%) 41/122 (34) 2/6 (33) 0/8 15/38 (40) 24/70 (34) 0.2
Symptoms:
ILI*** – n/n (%) 112/122 (92) 6/6 (100) 8/8 (100) 33/38 (87) 65/70 (93) 0.5
Fever/Chills – n/n (%) 122/122 (100) 6/6 (100) 8/8 (100) 38/38 (100) 70/70 (100)
Cough – n/n (%) 113/122 (93) 5/6 (83) 8/8 (100) 34/38 (90) 66/70 (94) 0.5
Sore Throat – n/n (%) 77/122 (63) 4/6 (67) 7/8 (88) 28/38 (74) 38/70 (54.) 0.1
Myalgia – n/n (%) 103/122 (84) 6/6 (100) 7/8 (88) 33/38 (87) 57/70 (81) 0.6
Household Contacts – n 320 16 23 99 182
Age (years) – median (IQR) 29.3 (15.0) 31.5 (9–41) 27 (26–39) 33 (12–41) 34.5 (17–42)
Age,14 years – n/n (%) 76/320 (24) 6/16 (38) 5/23 (22) 28/99 (28) 37/182 (20) 0.3
Sex, male – n/n (%) 149/320 (47) 8/16 (56) 8/23 (35) 49/99 (50) 84/182 (46) 0.6
Vaccinated* – n/n (%) 20/320 (6) 2/16 (13) 1/23 (4) 11/99 (11) 6/182 (3) 0.03
Influenza-positive household
contacts - n
67 6 11 22## 28##
Vaccinated* – n/n (%) 2/67 (3) 0/6 0/11 0/22 2/28 (7) 0.7
Antiviral Therapy** – n/n (%) 8/67 (12) 1/6 (17) 2/11 (18) 4/22 (18) 1/28 (4) 0.2
Symptoms (among non-vaccinated
secondary cases):
ILI*** – n/n (%) 41/65 (63) 5/6 (83) 7/11 (64) 13/22 (59) 16/26 (62) 0.7
Fever/Chills – n/n (%) 44/65 (68) 5/6 (83) 7/11 (64) 14/22 (64) 18/26 (69.0) 0.8
Cough – n/n (%) 53/65 (82) 6/6 (100) 9/11 (82) 17/22 (73) 21/26 (81) 0.7
Sore Throat – n/n (%) 38/65 (59) 2/6 (33) 8/11 (73) 12/22 (55) 16/26 (62) 0.5
Myalgia – n/n (%) 50/65 (77) 4/6 (67) 9/11 (81) 15/22 (68) 22/26 (85) 0.4
Asymptomatic# – n/n (%) 9/65 (14) 0/6 (0) 2/11 (18) 4/22 (18) 3/26 (12) 0.7
*Vaccination defined as vaccination against pandemic influenza in season 2009/10 and trivalent seasonal vaccine in 2007/08, 2008/09 & 2010/11, at least 14 days before
symptom onset in index patient or secondary household case. ** Antiviral therapy defined as treatment with oseltamivir or zanamivir within 2 days of symptom onset.
*** ILI = Influenza-like-illness.
#Asymptomatic = no fever, no cough, no sore throat.
##Includes participants from all three intervention groups in seasons 3 and 4.
doi:10.1371/journal.pone.0051653.t001
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symptom score ranged from 0 points (no symptoms) to 9 points (all
symptoms with maximum severity).
Laboratory Analysis
Nasal wash specimens were analysed by qRT-PCR at the
Centre for Biological Security, Unit for Highly-Pathogenic
Viruses (season 3) and the National Reference Centre for
Influenza (seasons 1, 2 and 4) both located at the Robert Koch
Institute in Berlin, Germany. Nasal swabs were taken up by
3 mL of Minimum Essential Medium Eagle containing 10,000
U/ml of streptomycin/penicillin and afterwards treated just like
nasal wash specimens. RNA was extracted using either the
MagNA Pure 96 DNA and Viral Nucleic Acid Small Volume
Kit (Roche Applied Science, Mannheim, Germany) on MagNA
Pure 96 instrument (Roche Applied Science) or the MagAttract
Viral RNA M48 Kit (Qiagen GmbH, Hilden, Germany)
according to the manufacturer’s suggestions. Details about the
PCR protocol as well as primer and probe sequences have been
published elsewhere [11]. Quantitative results were expressed as
log of RNA copies/ml (log Copies/ml). A convenience sample
of specimens from seasons 1 and 2 was also tested for
quantification of infectious viruses by using a plaque assay in
MDCK cell culture monolayer. The results are presented as
plaque-forming units (PFU)/ml.
Statistical Analysis
We defined the serial interval as the number of days between
symptom onset of the household index case and symptom onset of
the first secondary case. Other secondary household cases were
only included in the calculation if their symptom onset occurred
on the same day as the first secondary household case. Further
household cases were not taken into account for the calculation of
the serial interval because it was not possible to decide if they were
secondary or in fact tertiary cases.
For descriptive analysis we used Wilcoxon’s ranksum test for
numerical and chi-square-tests for categorical variables. For all
analyses, we used two-sided tests and considered p-values of,0.05
as statistically significant. We performed analyses with Stata
software, version 11 (Stata Corporation, Texas, USA).
Ethics Statement
The Ethics Committee of the Charité Universitätsmedizin
Berlin approved of the study (EA1/043/07).
Results
Study Population
We recruited 127 households over the four study periods. Five
households had to be excluded from analysis because the initial
rapid antigen test could not be confirmed by RT-PCR or the
participants declined further participation, respectively (figure 1).
The remaining 122 households comprised 442 participants (122
index patients and 320 household contacts). The index patient of
six households (22 participants) was infected with seasonal/
prepandemic influenza A(H1N1) infection (recruited in season
1), of eight households (31 participants) with influenza A(H3N2)
(season 2), of 38 households (137 participants) with influenza B
(seasons 1, 2, and 4) and of 70 households (252 participants) with
influenza A(H1N1)pdm09 (seasons 3 and 4). This resulted in 12
laboratory confirmed cases of seasonal/prepandemic influenza
A(H1N1)(6 index, 6 household contacts), in 19 laboratory
confirmed cases of influenza A(H3N2) (8 index, 11 household
contacts), in 60 laboratory confirmed cases of influenza B (38
index, 22 household contacts), and in 98 laboratory confirmed
cases of influenza A(H1N1)pdm09 (70 index, 28 household
contacts).
Figure 2. Viral shedding in laboratory confirmed symptomatic index and secondary cases. Median and interquartile range of log Copies/
ml in index patients (green line) and secondary symptomatic cases (orange line) as well as individual values for participants with presymptomatic
shedding (blue dots). For negative tests a value of 0 was used. By definition, symptom onset started on day 1.
doi:10.1371/journal.pone.0051653.g002
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Baseline Characteristics
Table 1 shows the baseline characteristics of index patients and
household contacts stratified by influenza virus (sub)type of the
household. In all study seasons index patients were almost
exclusively children, while most household contacts were adults.
The proportion of vaccinated household contacts differed signif-
icantly between (sub)types (p = 0.03, table 1), with the highest
proportion observed in seasonal/prepandemic influenza A(H1N1)
households (13%) and the lowest in A(H1N1)pdm09 (3%)
households. Sixty-seven household contacts contracted influenza.
Among 20 vaccinated household contacts two (10%) became
laboratory confirmed cases (both A(H1N1)pdm09, both symptom-
atic), while among 300 non-vaccinated contacts 65 (22%) were
laboratory confirmed cases, of whom 56 (86%) were symptomatic
and 9 (14%) asymptomatic.
The overall proportion of asymptomatic/subclinical cases
among non-vaccinated secondary cases (9/65; 14%) was de-
pendent on age: while none of 21 non-vaccinated child cases were
asymptomatic, 21% (9/44) of non-vaccinated adult cases were
asymptomatic/subclinical (p = 0.03). Other variables such as sex,
vaccination or antiviral therapy of the infecting index patient did
not differ significantly between symptomatic and asymptomatic/
subclinical secondary cases.
Symptoms of index patients (n = 122) as well as non-vaccinated
secondary cases (n = 65) did not differ significantly between the
virus (sub)types. 62% of A(H1N1)pdm09 non-vaccinated second-
ary household cases had symptoms consistent with ILI, similar to
that of non-vaccinated A(H3N2) secondary cases (64%) and non-
vaccinated secondary influenza B cases (59%), but lower than non-
vaccinated secondary seasonal/prepandemic influenza A(H1N1)
cases (83%). Differences among the groups were not statistically
significant (p = 0.7).
Serial Interval
On the basis of five secondary cases the mean serial interval for
seasonal/prepandemic influenza A(H1N1) was estimated at
2.462.1 days (mean, standard deviation). For seasonal influenza
A(H3N2), influenza B and influenza A(H1N1)pdm09 the mean
serial intervals were 1.960.7 days (based on 7 secondary cases),
2.461.5 days (based on 14 secondary cases) and 2.461.5 days
(based on 19 cases), respectively.
Shedding Analyses
Blood and stool samples. In seasons 1 and 2, we obtained
a total of 18 EDTA blood samples from four laboratory confirmed
cases – all collected from symptomatic secondary household cases
before and during the first three days after symptom onset. All of
Figure 3. Viral shedding and symptom scores in patients with influenza-like illness symptoms. Viral shedding (expressed as median of
log Copies/ml) and symptom scores (expressed as median) for all cases with influenza-like illness symptoms. Top left: viral shedding, top middle:
symptom scores; top right: seasonal/prepandemic influenza A(H1N1), bottom left: influenza A(H1N1)pdm09, bottom middle: influenza A(H3N2),
bottom right: influenza B. For negative tests a value of 0 was used.
doi:10.1371/journal.pone.0051653.g003
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them were secondary household cases. Results for all samples were
qRT-PCR negative. Seven index patients provided a total of seven
stool samples. Results of qRT-PCR were also negative for these
samples.
Shedding curves. Analysis of shedding curves among symp-
tomatic influenza patients included data from 180 individuals (122
index patients, 58 household contacts). Figure 2 shows an analysis
of the median viral load by illness day and includes all virus
(sub)types and all laboratory confirmed cases, stratified for index
and secondary cases. The shedding curve of index patients starts
from a high point on the first illness day and declines from there.
The number of copies detected in specimens from secondary cases
Figure 4. Symptomatic and asymptomatic shedding in influenza patients. Median and interquartile range of log Copies/ml in 6
asymptomatic influenza patients (green; 2 A(H1N1)pdm09, 2 A(H3N2), 2 B) as well as in influenza patients with influenza-like illness of any type or
subtype (red).
doi:10.1371/journal.pone.0051653.g004
Figure 5. Viral shedding and symptom scores in patients with influenza-like illness stratified by age. Viral shedding (expressed as
median and interquartile range of log Copies/ml) and symptom scores (expressed as median and interquartile range) for adult and child patients with
influenza-like illness symptoms. adults - continuous line, children - dashed line) starting on the day of symptom onset. For negative tests a value of
0 was used.
doi:10.1371/journal.pone.0051653.g005
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starts on a lower level than those among index cases, but reaches
a peak on illness day 3. From that time point both curves are
largely the same. We detected presymptomatic shedding primarily
on the first day before symptom onset. The proportion of
influenza-positive presymptomatic samples was 30% (12/40),
10% (2/20), 9% (1/11), 20% (1/5), 25% (1/4) and 0% (0/3) on
the first, second, third, fourth, fifth and sixth day before symptom
onset, respectively (corresponding to illness days 21, 22, 23, 24
25 and 26 (when the day before symptom onset is noted as day
21). Out of five individuals of whom samples beyond three days
before symptom onset were available shedding was observed in
one. This patient was infected with influenza A(H1N1)pdm09 and
shed influenza virus on three out of five days prior to symptom
onset. To illustrate presymptomatic shedding, we show individual
viral load values before symptom onset in figure 2.
Further analysis of shedding curves was done for influenza
patients with ILI comprising 112 (92% of 122) of index and 42
(63% of 67) secondary cases. Shedding curves stratified by virus
(sub)type are presented in figure 3. All (sub)types display
a comparable shedding profile with the highest viral loads on
illness days 1–3 followed by a steady decline. Median viral load of
influenza A(H1N1)pdm09 was lower than that of the other
(sub)types on days 3–6. Also noteworthy is the shedding curve of
influenza B which starts from the lowest point, rises to it’s peak by
day 2 and 3 and continues to have the highest viral load until day 7
(figure 3, upper panel, left). Symptom scores followed a comparable
pattern as the shedding curves (figure 3, upper panel, middle)
peaking on illness day 2 in all (sub)types. In contrast to the other
(sub)types, however, the median of symptoms score for seasonal/
prepandemic influenza A(H1N1) did not recede completely by the
end of the participants’ observation period on illness day 8.
Specimens from asymptomatic/subclinical individuals were
available from 6 participants (2 with A(H1N1)pdm09, 2 with
A(H3N2) and 2 with influenza B infections) on day 1, from 3
participants on day 2 and from 4 participants on day 3. The
amount of shedding does not differ substantially from the values
pooled from all influenza patients with ILI (Figure 4).
Stratification by age (children vs. adults) showed similar profiles
in influenza-positive ILI-patients for both groups until study day 6
(Figure 5). Differences between the two age groups were not
statistically significant.
The effect of antiviral therapy on viral shedding and symptoms
of influenza patients with ILI is shown in figure 6. The symptom
curve suggests a milder clinical course and a slightly earlier
resolution of symptoms in the treatment group (figure 6). We
found significantly lower symptom scores in the group with timely
treatment on illness days 3 (p= 0.0007) and 4 (p= 0.001).
Figure 6. Influence of antiviral therapy and vaccination on viral shedding and symptoms in influenza patients. Viral shedding
expressed as median and interquartile range of log Copies/ml and influenza symptoms expressed as median and interquartile range. Top: patients
with influenza-like illness, by antiviral treatment, bottom: not vaccinated patients (all with influenza-like illness) in green, vaccinated patients (with
any symptoms) in orange. For negative tests a value of 0 was used.
doi:10.1371/journal.pone.0051653.g006
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Five index patients (three with influenza B, one each with
seasonal/prepandemic influenza A(H1N1) and influenza
A(H1N1)pdm09, respectively) and two secondary cases (both with
influenza A(H1N1)pdm09) contracted influenza despite being
vaccinated. Of 43 specimens collected from these vaccinated
patients 27 (63%) tested positive by qRT-PCR, and of 1379
specimens from non-vaccinated cases 751 (55%) tested positive.
The difference between these groups was not statistically
significant. The viral shedding and the symptom profile of
vaccinated cases) were comparable to those of non-vaccinated
ILI cases (figure 6, lower panel, left).
The shedding profiles measured by viral culture for influenza
viruses of (sub)types seasonal/prepandemic A(H1N1), A(H3N2)
and influenza B (figure 7, continuous lines) compared with
shedding profiles measured by qRT-PCR in ILI patients (figure 7,
dashed lines) showed that the duration of viable virus was shorter
for all examined (sub)types (seasonal/prepandemic influenza
A(H1N1): 4 days (PCR: 8 days), influenza A(H3N2): 6 days
(PCR: 7–9 days) and influenza B: 5 days (PCR: 9 days).
Discussion
In this study, conducted in Germany during four consecutive
influenza seasons (including the pandemic and first postpandemic
wave), we provide important data on virologic and epidemiologic
parameters of pre- and postpandemic influenza viruses, i.e.
seasonal/prepandemic A(H1N1), pandemic (H1N1)pdm09,
A(H3N2) and B. The household based approach to gather this
type of information is an efficient and appropriate design to collect
those kind of data in the natural setting. Advantages are that it
permits identification and measurement of presymptomatic and
asymptomatic shedding and that clinical symptoms of secondary
cases can be described without surveillance bias because secondary
household cases were identified through serial testing without the
use of a case definition.
Overall 63% of non-vaccinated secondary household cases had
an ILI-syndrome and the proportion of asymptomatic/subclinical
secondary cases was 14%. Frequency distribution of clinical
symptoms did not differ between A(H1N1)pdm09 cases and non-
pandemic influenza cases. These observations are similar to results
of other studies that analysed naturally occurring pandemic [12]
or prepandemic/seasonal infections [6,13]. However, we might
have missed short-lived shedding in infected asymptomatic/
subclinical participants, as we did not conduct additional serologic
testing. Interestingly, 21% of adult secondary cases were
asymptomatic/subclinical, while all children that contracted
influenza were symptomatic. If replicated in other studies this
finding may be important for public health measures as children
are known to play an important role in the transmission of
influenza, and high rates of asymptomatic/subclinical infection in
this age group might diminish the probability for the success of
potential prevention strategies.
Recent research has shown that serial intervals may be different
in different settings, i.e. school, community or household [14].
From our household data we estimated the serial interval for
A(H1N1)pdm09 to be 2.4 days which is similar to an estimate of
2.6 days derived from a review of thirteen studies [15]. The true
serial interval may be different because we have discarded
secondary household cases that occurred at least one day after
the onset of the first secondary case in the household because we
do not know if this case represents a secondary or tertiary case. For
seasonal influenza viruses, our estimates were 2.4 days (seasonal/
prepandemic A(H1N1)), 1.9 days A(H3N2) and 2.4 days (B),
respectively. Two other publications on prepandemic influenza
approximated the serial interval as 3.6 days (no (sub)type specified)
[16] or as 2 days for A(H3N2) [17]. In a review of challenge studies
conducted before the pandemic (H1N1) 2009, Carrat et al.
computed the generation time of seasonal influenza viruses as
2.3 days (H1N1), 3.1 days (H3N2) and 3.4 days (B) [5]. Overall it
Figure 7. Viral load in specimens measured by qRT-PCR or viral culture, by (sub)type. Viral load in specimens of patients with influenza-
like illness measured by qRT-PCR (expressed as median of log Copies/ml) as well as in patients with any symptoms measured by viral culture
expressed as median of log Plaque forming units (PFU), stratified by (sub)type. No data available for influenza A(H1N1)pdm09. For negative tests
a value of 0 was used.
doi:10.1371/journal.pone.0051653.g007
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appears that serial intervals are similarly short for all virus
(sub)types. This supports the notion - based on the experience
from controlled trials on the effect of non-pharmaceutical
interventions - that any measures aiming to prevent (household)
transmission must be implemented quickly to be effective [8,18].
Published reports suggest that influenza RNA may be detected
in blood at best sporadically [19–21]. We also were not able to
demonstrate viraemia in selected cases of seasonal influenza. In
contrast, one study conducted during the influenza pandemic
(H1N1) 2009 detected viral RNA in the blood of 14 out of 139
patients hospitalised with influenza. However, viraemia was only
seen in severely ill patients [22]. Influenza virus RNA (occasionally
also viable virus) has been identified in stool samples of patients
suffering from seasonal influenza [23]. Studies on A(H1N1)pdm09
[24,25] have also been able to demonstrate viral RNA in stool
samples from both community [24] and hospitalised patients [25].
The stool sample of one hospitalised child with a very high viral
load even yielded a positive culture [26]. In our small collection of
stool samples we did not identify viral RNA, perhaps because none
of the participants was severely ill which might predispose to viral
shedding in blood or feces.
Pooled shedding data of all four influenza virus (sub)types
examined in this study showed presymptomatic shedding on the
day preceeding symptom onset in 30% of participants providing
samples on that day. This is consistent with a proportion of 27%
for seasonal influenza A (H1N1 or H3N2) cases and 29% for
influenza B cases as published by Lau et al. [13]. Presymptomatic
shedding beyond the first day is difficult to interpret and might be
explained by gradual disease onset or an exceptionally latency
period in an individual case. Overall, published reports on
presymptomatic shedding are rare, likely due to the methodolog-
ical difficulties in obtaining data on this subject. Donnelly
estimated that a substantial proportion (15–25%) of transmission
of pandemic (H1N1)pdm09 occurs from viral shedding before
disease onset [27]. This would be supported by our data although
a direct comparison is not possible. Another study that investigated
three case clusters very early in the pandemic (H1N1) 2009 came
to the conclusion that transmission may have occurred during the
presymptomatic phase [26]. Unfortunately, we cannot provide
information on the question of disease transmission during
presymptomatic shedding periods.
The degree of viral load associated with asymptomatic (or
subclinical) infection could be assessed in 6 participants only and
suggested that the amount of shedding may be similar to that in
symptomatic influenza patients with ILI symptoms. This finding
concurs with results from Loeb [7] and Lau [13]. While Loeb
found that asymptomatic shedding lasted 4.0 days [7] our data did
not suffice to determine the duration of shedding in asymptom-
atic/subclinical infections.
The shedding curves of the four virus (sub)types in ILI-patients
do not show considerable differences, however two points can be
made: (i) viral load of influenza A(H1N1)pdm09 was rather lower
and shorter than in patients infected with seasonal (sub)types, its
profile is similar to seasonal influenza A viruses with an early peak
on illness days 1 or 2 and a steady decline thereafter (consistent
with data from Cowling et al. [6]); (ii) upon close examination, the
molecular shedding curve of influenza B starts from the lowest
point, peaks by day 3 and continues to have the highest viral load
of all viruses. Other publications on shedding of influenza B are
scarce. Lau et al. also based their investigations on naturally
occurring infections and found, similar to us, a peak for seasonal A
viruses on days 1 or 2, whereas the shedding pattern of influenza B
was delayed to day 3 [13]. Also the influenza B shedding curve
(based on a single study) presented in the review by Carrat et al.
[5] demonstrates a slow increase with a peak on the 4th day after
inoculation, corresponding approximately to illness day 3. Thus,
molecular viral shedding of both seasonal and pandemic influenza
A viruses may peak one or two days earlier than influenza B.
In contrast, symptom curves of ILI patients with infections of all
four (sub)types appear to follow a very similar course (figure 3, top
panel, middle picture). All peak on day 2 and decrease steadily
thereafter until illness days 8 or 9. Again, other investigators have
reported similar findings [6,13] specifying that systemic signs, such
as fever, subside first, followed by symptoms of the lower and
finally of the upper respiratory tract.
Based on the population of ambulatory patients investigated we
found no evidence that the amount of shedding is particularly
higher in children, nor that duration of viral shedding is
significantly longer in children compared to adults. A few smaller
studies on influenza (H1N1)pdm09 have also not been able to
show significant age-dependent differences in the duration of viral
shedding [28,29], although others, both in seasonal [30] and
pandemic influenza A(H1N1)pdm09 [31], have. The latter study
was conducted among patients hospitalised with A(H1N1)pdm09
and demonstrated very clearly that duration of shedding is
prolonged in hospitalised children,13 years [31]. While all of our
patients had infections that were mild enough to be treated on an
out-patient basis, it is possible that an age difference in viral
shedding becomes particularly visible when the course of disease is
severe.
In 1997, a randomized controlled trial with experimental
infection of human volunteers demonstrated that very early
administration of oseltamivir (in this case 28 hours after in-
oculation, i.e. approximately at the time of symptom onset) can
reduce viral shedding and significantly ameliorate the clinical
course [32]. Two randomized trials where influenza patients with
naturally acquired infection were treated with oseltamivir no later
than 36 hours after symptom onset also showed a significant
reduction of severity, but differed in their assessment of the effect
on viral shedding [33,34]. Observational studies where require-
ments for oseltamivir treatment permitted treatment inception up
to 48 hours after symptom onset often failed to demonstrate
significant effects in viral shedding parameters [6,28,29] and our
study is no exception in this regard.
To our knowledge, the effect of vaccination on viral shedding
among patients who have become infected despite having been
vaccinated has been investigated rarely.
We identified seven influenza-positive patients who had been
vaccinated: two symptomatic household contacts and five index
patients. We were surprised to observe that both the proportion of
positive samples as well as the viral load among vaccinated cases
was similar compared to that among non-vaccinated cases. The
only study known to us where these questions have been studied
[35] reported similar results. Also this finding may have important
implications for the parameterisation of modelling studies. Caution
should be taken to avoid misinterpretation, though. It does not
mean that the vaccine is not effective. Of 67 vaccinated household
contacts only two (3%) contracted influenza. Similarly, in the cited
publication by Couch et al., vaccine efficacy for symptomatic
illness was 93% and for any shedding 70%, but the probability of
being asymptomatic among those who shed was 86% (6/7) in
vaccinated and 45% (5/11) in non-vaccinated.
To compare molecular data on viral load with viral culture we
directly cultured viruses from the seasonal/prepandemic (sub)types
A(H1N1), A(H3N2) and B. Cultures of A(H1N1)pdm09 were not
done. We observed that samples from illness days 4–6 cease to
contain viable virus, but viral RNA may still be detectable until
illness days 7–9. This compares well with data from seasonal
Properties of Seasonal and Pandemic Influenza
PLOS ONE | www.plosone.org 9 December 2012 | Volume 7 | Issue 12 | e51653
influenza obtained from an experimental study in volunteers
where the duration of shedding in untreated adult volunteers using
viral culture was found to be 4.8 days [5].
There are some limitations which need to be considered in the
context of this study. As recruitment of index patients was based
on rapid antigen testing and an increased level of viral shedding is
associated with increased rapid test sensitivity [36], our data on
viral shedding and the course of illness may represent (likely more
severe) infections associated with generally increased levels of
shedding. In addition, most analyses of shedding characteristics
were done among ILI patients which are likely not representative
of all influenza patients. For logistic reasons, viral culture could
only be performed during seasons 1 and 2. Thus sample sizes were
small and comparability with other studies is limited. Furthermore,
sample collection differed slightly between seasons 1/2 and 3/4
with household visits scheduled every day during the first two and
every second day during the second two seasons. There is a slight
chance that we may have missed secondary, very low-grade and/
or short-lived, asymptomatic/subclinical infections between these
visits. Overall, the quantity of data and hence statistical power was
limited, so we may not have found differences that may in fact
exist.
The strengths of our study are (i) data collection from naturally
occurring infections over the course of four seasons with
circulation of four different (sub)types, (ii) prospective identifica-
tion, collection of specimens and questionnaire data from study
participants, which enabled us to obtain a true overall clinical
picture of influenza cases.
In summary, our study addresses several important questions on
clinical manifestation, duration of infectiousness, viral shedding
patterns, including shedding before symptom onset and in
asymptomatic/subclinical patients, as well as the effect of
vaccination and antiviral therapy on viral shedding. Important
single results include the finding that children do not seem to be
infected asymptomatically, that shedding one day before symptom
onset may occur in one third of influenza patients, that
asymptomatic/subclinical influenza patients occur rarely, but viral
load (and probably infectiousness) may be substantial, and
vaccinated influenza patients do not show different shedding
patterns compared to non-vaccinated cases with ILI. Overall
results do not show marked differences between seasonal influenza
(sub)types and influenza A(H1N1)pdm09.
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